$CGTX

Taiho Pharmaceutical and Cullinan Therapeutics said their Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line advanced NSCLC with EGFR exon 20 insertion mutations met the primary endpoint at interim analysis. They reported statistically significant, clinically meaningful progression-free survival improvement versus chemotherapy alone, without disclosing figures. Zipalertinib is under FDA review for previously treated patients.

COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update Purchase, NY – August 6, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative

The article says Canada’s biotech sector has seen a strong 12-month run, with listed companies raising $2.4 billion on public markets and excluding Apotex’s $1.5 billion June IPO. It highlights several Canadian biotechs, especially AbCellera Biologics, which plans to report key human efficacy results this quarter for a menopause hot-flash treatment. It also notes foreign investors dominate funding.

Cognition Therapeutics said the FDA, in written meeting feedback, agreed that psychosis in dementia with Lewy bodies (DLB) could support an approvable outcome and aligned on key aspects of a pivotal NDA trial for zervimesine (CT1812). The Phase 3 program is expected to start mid-2027; it will randomize patients to 100 mg once-daily zervimesine vs placebo for nine months, using NPI as a primary endpoint.

COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001455365 0001455365 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report

Cognition Therapeutics (Nasdaq: CGTX) said CEO Lisa Ricciardi will present at two investor conferences in June, sharing updates on the company’s planned registrational program for dementia with Lewy body (DLB) psychosis. The Jefferies Global Healthcare Conference is June 4, 2026 (1:25 p.m. ET), with an on-demand H.C. Wainwright summit starting June 15. Webcasts will be available on the company’s site.

Five brokerages have given Cognition Therapeutics (NASDAQ:CGTX) a "Moderate Buy" consensus rating, with an average 1-year price target of $3.33. Institutional ownership has increased significantly to 43.35%, driven by major stake builds and new positions. Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on Alzheimer's, with its lead candidate CT1812 currently in multiple Phase 2 trials.

Study conducted in collaboration with the Alzheimer's Clinical Trials Consortium Study conducted in collaboration with the Alzheimer's Clinical Trials Consortium ...

Here is how ANI Pharmaceuticals (ANIP) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.

Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.